ValuEngine upgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a buy rating in a research note published on Friday morning.
A number of other research firms also recently issued reports on ANGO. Raymond James Financial raised AngioDynamics from a market perform rating to an outperform rating and set a $16.33 price objective on the stock in a research note on Tuesday, April 3rd. UBS upgraded AngioDynamics from a market perform rating to an outperform rating in a report on Tuesday, April 3rd. Canaccord Genuity lifted their target price on AngioDynamics from $16.50 to $17.00 and gave the stock a hold rating in a report on Monday, April 2nd. BidaskClub upgraded AngioDynamics from a hold rating to a buy rating in a report on Friday, March 30th. Finally, Zacks Investment Research cut AngioDynamics from a buy rating to a hold rating in a report on Friday, January 26th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $17.87.
NASDAQ:ANGO opened at $18.88 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.84 and a current ratio of 2.88. AngioDynamics has a 1 year low of $14.80 and a 1 year high of $19.25. The company has a market capitalization of $694.88, a price-to-earnings ratio of 25.86, a PEG ratio of 1.70 and a beta of 1.00.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. The business had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. equities analysts expect that AngioDynamics will post 0.74 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in ANGO. SG Americas Securities LLC purchased a new position in shares of AngioDynamics in the 3rd quarter worth approximately $143,000. Crossmark Global Holdings Inc. purchased a new position in shares of AngioDynamics in the 4th quarter worth approximately $172,000. Trexquant Investment LP purchased a new position in shares of AngioDynamics in the 3rd quarter worth approximately $175,000. Teacher Retirement System of Texas purchased a new position in shares of AngioDynamics in the 4th quarter worth approximately $201,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of AngioDynamics in the 4th quarter worth approximately $297,000. Hedge funds and other institutional investors own 97.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “AngioDynamics (ANGO) Upgraded to Buy at ValuEngine” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/09/angiodynamics-ango-upgraded-to-buy-at-valuengine.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.